Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites

被引:78
作者
Chen, Xiao-Jia [1 ]
Zhang, Xiao-Jing [1 ]
Shui, Yan-Mei [2 ]
Wan, Jian-Bo [1 ]
Gao, Jian-Li [2 ]
机构
[1] Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Macau, Peoples R China
[2] Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
GINSENG SAPONIN METABOLITE; ACTIVATED PROTEIN-KINASE; ADENOCARCINOMA A549 CELLS; COLON-CANCER GROWTH; COMPOUND-K; IN-VITRO; PANAX-NOTOGINSENG; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; GLUCOCORTICOID-RECEPTOR;
D O I
10.1155/2016/5738694
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Recently, most anticancer drugs are derived from natural resources such as marine, microbial, and botanical sources, but the low success rates of chemotherapies and the development of multidrug resistance emphasize the importance of discovering new compounds that are both safe and effective against cancer. Ginseng types, including Asian ginseng, American ginseng, and notoginseng, have been used traditionally to treat various diseases, due to their immunomodulatory, neuroprotective, antioxidative, and antitumor activities. Accumulating reports have shown that ginsenosides, the major active component of ginseng, were helpful for tumor treatment. 20(S)-Protopanaxadiol (PDS) and 20(S)-protopanaxatriol saponins (PTS) are two characteristic types of triterpenoid saponins in ginsenosides. PTS holds capacity to interfere with crucial metabolism, while PDS could affect cell cycle distribution and prodeath signaling. This review aims at providing an overview of PTS and PDS, as well as their metabolites, regarding their different anticancer effects with the proposal that these compounds might be potent additions to the current chemotherapeutic strategy against cancer.
引用
收藏
页数:19
相关论文
共 200 条
[1]  
Akao T, 1998, BIOL PHARM BULL, V21, P245, DOI 10.1248/bpb.21.245
[2]  
[Anonymous], 2008, CHIN J INTEGR MED, V14, P33, DOI [10.1007/s11655-007-9002, 10.1007/s11655-007-9002-6]
[3]  
[Anonymous], CHINESE J CLIN ONCOL
[4]  
[Anonymous], BIOTECHNOL BIOPROC E
[5]  
[Anonymous], ZHONGHUA BEN CAO JIN
[6]  
[Anonymous], 2008, CHIN MED-UK, DOI DOI 10.1186/1749-8546-3-8
[7]  
[Anonymous], WAKAN IYAKUGAKU ZASS
[8]  
[Anonymous], CHINESE J CANC PREVE
[9]  
[Anonymous], CHINESE J INTEGRATIV
[10]  
[Anonymous], 2005, BENCAO GANGMU